News & Trends2026-04-20Carelogy編集部
FeliAIM: Japan's AIM Kidney Drug for Cats — Filed for Approval, Now Under Review (Aug 2026 Update)
Japan's AIM protein drug for feline chronic kidney disease now has a name — FeliAIM — and was formally filed with the Ministry of Agriculture on April 24, 2026. It is currently under review. Clinical trial data, mechanism, expected cost, and what owners should do now.
What Is the AIM Drug? A Groundbreaking Approach to the Root Cause of Feline CKD
Feline chronic kidney disease (CKD) affects approximately 81% of cats over 15 years old and is the leading cause of death in cats. Until now, treatments could only slow progression — no cure existed.
The AIM drug may fundamentally change this.
How AIM protein works:
AIM (Apoptosis Inhibitor of Macrophage) is a protein naturally present in the blood of all mammals. In healthy animals, AIM acts as a "cleanup crew," removing dead cell debris (waste) that accumulates in kidney tubules.
However, cats have a structural defect in their AIM:
- In humans and dogs, AIM floats freely in blood and reaches the kidneys when needed
- Cat AIM remains tightly bound to IgM antibodies and cannot detach
- This means AIM never reaches the kidneys → waste accumulates → inflammation → kidney failure
This is why cats develop kidney disease at abnormally high rates compared to other mammals. The AIM drug provides functional AIM protein from outside, compensating for this feline-specific weakness.
The discovery was made by Dr. Toru Miyazaki — formerly a professor at the University of Tokyo, now director of the AIM Institute of Medical Science and CEO of IAM CAT Co., Ltd. — who raised approximately ¥14 million through crowdfunding in 2021 to accelerate research.
Zou jij het merken als er iets mis is?
Katten verbergen pijn. CatsMe gebruikt AI om op een foto van het gezicht van je kat te controleren op tekenen van pijn in de uitdrukking. CatsMe stelt geen diagnoses; maak je je zorgen, neem dan contact op met je dierenarts.
Clinical Trial Data: Disease Progression Halted in Stage 3 Cats
Clinical trials for the AIM drug were conducted jointly by the AIM Institute of Medical Science and IAM CAT Co., Ltd.
Trial overview:
- Subjects: Cats with CKD Stage 3 (creatinine 2.9-5.0 mg/dL per IRIS criteria)
- Administration: Injection (exact dosing intervals not yet publicly disclosed)
- Follow-up: Months to years of monitoring
Confirmed effects:
- Disease progression halted: In cats that began treatment at Stage 3, further deterioration of kidney function was suppressed
- Improved general condition: Recovery of appetite, increased activity levels, and improved coat quality were reported
- Long-term survival: Cases of cats surviving 5+ years after starting AIM treatment have been documented
Critical caveats — this is NOT a "miracle cure":
- It does not regenerate damaged kidney tissue
- Effectiveness is limited in Stage 4 (end-stage) disease
- The effect is "halting progression," not "reversing damage"
- Early detection and early treatment maximize benefit
Expected benefit by CKD stage:
| CKD Stage | Creatinine | Expected Benefit |
|---|---|---|
| Stage 1 | <1.6 mg/dL | Excellent — preventive use possible |
| Stage 2 | 1.6-2.8 mg/dL | Excellent — significant slowing expected |
| Stage 3 | 2.9-5.0 mg/dL | Good — efficacy confirmed in trials |
| Stage 4 | >5.0 mg/dL | Limited — less effective at end-stage |
Approval Timeline and Expected Cost
Current status (as of August 2026):
1. ✅ Clinical trials completed
2. ✅ Stability testing completed (March 2026)
3. ✅ Filed with Japan's Ministry of Agriculture on April 24, 2026 (done) — submitted by IAM CAT Co., Ltd. (CEO Toru Miyazaki) under the product name FeliAIM. Source: AIM Institute of Medical Science / IAM CAT announcement
4. ⏳ Review period (typically 6-12 months) — where things stand now
5. 🎯 Target availability: Late 2026 to early 2027
About the name FeliAIM: it combines *Felis* (Latin for cat) with the active ingredient AIM. The naming, the review process and the expected timeline to prescription are covered separately in our FeliAIM filing follow-up. Note that filing is not approval — the drug has not been approved or launched yet, and it will only reach clinics after review is complete.
Expected cost:
Official pricing will be announced after approval, but estimates can be made based on comparable veterinary drugs:
- New veterinary drugs typically cost ¥3,000-10,000 per dose
- If ongoing treatment is needed, monthly costs of ¥5,000-15,000 are expected
- Pet insurance coverage is possible but will vary by provider
Cost-effectiveness perspective:
Conventional CKD management (prescription diet + regular testing + fluid therapy) costs ¥10,000-30,000/month. If AIM can halt progression, it may reduce long-term treatment costs.
What owners can do now to prepare:
1. Get regular blood work done (annually; twice yearly for cats 7+) → Health check guide
2. Track BUN, creatinine, and SDMA values over time (if your cat is already drinking and urinating more, rule out the causes first)
3. Consider pet insurance enrollment (in case the new drug becomes covered)
4. Discuss the AIM drug with your regular veterinarian
How AIM Fits with Existing CKD Management
Even after AIM becomes available, conventional CKD management will not become obsolete. In fact, AIM combined with existing therapies is expected to be the most effective approach.
Conventional therapies remain essential:
| Treatment | Purpose | Relationship with AIM |
|---|---|---|
| Kidney prescription diet | Reduce kidney burden via phosphorus/protein restriction | Use together |
| Subcutaneous fluids | Prevent dehydration, promote waste elimination | Combine as needed |
| Phosphorus binders | Control blood phosphorus levels | Use together |
| Antihypertensives | Prevent hypertension-related kidney damage | Use together |
| Hydration strategies | Reduce kidney workload | Always important |
What AIM changes is the "progression curve":
- Previously: Stage 2 → 3 → 4 → end-stage, irreversibly
- With AIM: Progression halted (or dramatically slowed) at a given stage
- Result: The period manageable with diet + fluids could be greatly extended
"Cats living to 30" — reality check:
Some media have reported that AIM could extend cat lifespan to 30 years, but this is overly optimistic. However, if CKD progression can be halted, more cats will live until they reach end-of-life from causes other than kidney failure. A realistic estimate is that average lifespan could increase by 3-5 years — which is still revolutionary.
Record changes in your cat's expression with CatsMe
In kidney disease, trends in weight, water intake, appetite and litter-box use matter. Whatever happens with new drugs, dated records help when you talk to your vet. CatsMe (by Carelogy Inc., Tokyo) is an app that uses AI to check a photo of a cat's face for signs of pain in its expression, informed by the Feline Grimace Scale (eyes, ears, muzzle, whiskers, head position). It does not diagnose disease, assess overall health or replace a veterinarian; if you are worried, contact your vet regardless of the result.
- Keep dated records of weight, water intake, meals and litter-box use to show your vet
- Records are kept per cat, so it works for multi-cat homes (iOS, Android and web, 14 languages)
- Developed with a background in university joint research; over 1 million checks run to date
Learn more about CatsMe →
Kun je antwoorden op "sinds wanneer is dit aan de gang?"
CatsMe gebruikt AI om op een foto van het gezicht van je kat te controleren op tekenen van pijn in de gezichtsuitdrukking, en bewaart gedateerde gegevens per kat die je met je dierenarts kunt bekijken. CatsMe stelt geen diagnoses.
AIMFeliAIMフェリエイム腎臓病新薬CKD宮﨑徹2026
FAQ
CatsMeWees voorbereid op het moment dat je voelt dat er iets niet klopt
Maak één foto en CatsMe controleert met AI het gezicht van je kat op tekenen van pijn. Bewaar gedateerde gegevens per kat om met je dierenarts te bekijken. CatsMe stelt geen diagnoses.